New Drug Application Submitted for Ibrutinib for Leukemia, Lymphoma

Share this content:

Janssen R&D announced that it has submitted a New Drug Application (NDA) for ibrutinib to the FDA for its use in the treatment of previously treated patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and for its use in the treatment of previously treated patients with mantle cell lymphoma (MCL). Ibrutinib is an investigational oral Bruton's tyrosine kinase (BTK) inhibitor.

The regulatory submission for ibrutinib is supported by data from two pivotal Phase 2 studies, one in relapsed/refractory CLL/SLL (PCYC-1102) and one in relapsed/refractory MCL (PCYC-1104).

In February 2013, ibrutinib was granted Breakthrough Therapy Designation from the FDA as monotherapy for the treatment of patients with relapsed/refractory MCL and for the treatment of patients with CLL/SLL with deletion of the short arm of chromosome 17 (del 17p).

For more information visit or

Read more about the use of ibrutinib for CLL here: New Therapeutic Approaches Changing the Management of Chronic Lymphocytic Leukemia

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs